Nemiralisib

N/A

Report date: 2025/06/05 20:00:13
NME

Base Information

Drug NameNemiralisib
Drug Alias Name奈米利塞GSK-2269557
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsActivated PI3K-delta syndromePulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsActivated PI3K-delta syndromePulmonary Disease, Chronic ObstructiveAsthma

Other Information

ATC CodeN/A
Related LinksN/A